Climb Competitors
| CLYM Stock | 4.47 0.31 6.49% |
Climb Bio vs Agenus Correlation
Pay attention - limited upside
The correlation between Climb Bio and AGEN is -0.72 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Climb Bio and AGEN in the same portfolio, assuming nothing else is changed.
Moving against Climb Stock
| 0.75 | MBIO | Mustang Bio | PairCorr |
| 0.75 | ACLX | Arcellx | PairCorr |
| 0.71 | BCT | Briacell Therapeutics | PairCorr |
| 0.69 | CRBP | Corbus Pharmaceuticals | PairCorr |
| 0.65 | RANI | Rani Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Climb Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Climb and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Climb Bio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Climb Stock performing well and Climb Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Climb Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ENTX | 3.73 | (0.71) | 0.00 | (2.03) | 0.00 | 8.57 | 22.41 | |||
| SPRO | 2.10 | (0.09) | 0.00 | (0.03) | 0.00 | 3.64 | 13.07 | |||
| MCRB | 4.33 | 0.04 | 0.00 | (0.02) | 6.70 | 9.13 | 54.10 | |||
| ANIX | 3.44 | (0.44) | 0.00 | (0.31) | 0.00 | 8.98 | 40.89 | |||
| ABOS | 4.21 | 0.38 | 0.08 | 0.41 | 4.52 | 9.94 | 31.48 | |||
| INO | 3.61 | (0.52) | 0.00 | (2.95) | 0.00 | 6.38 | 36.52 | |||
| ACTU | 3.18 | (0.64) | 0.00 | (0.36) | 0.00 | 5.40 | 20.01 | |||
| TTRX | 5.47 | (0.08) | 0.00 | 0.00 | 6.97 | 15.37 | 42.47 | |||
| VTGN | 5.61 | (1.56) | 0.00 | (1.76) | 0.00 | 7.61 | 96.59 | |||
| AGEN | 3.28 | (0.49) | 0.00 | (0.97) | 0.00 | 6.63 | 30.06 |
Cross Equities Net Income Analysis
Compare Climb Bio and related stocks such as Entera Bio, Spero Therapeutics, and Seres Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTX | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (1.2 M) | (11.2 M) | (10.3 M) | (10.8 M) | (10 M) | (12.2 M) | (13.1 M) | (8.9 M) | (9.5 M) | (8.6 M) | (9 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| ANIX | (1.7 M) | (4.3 M) | (10.1 M) | (9.6 M) | (1.4 M) | (5 M) | (5 M) | (14 M) | (11.6 M) | (10.1 M) | (12.9 M) | (13.6 M) | (9.8 M) | (12.6 M) | (10.9 M) | (9.8 M) | (9.3 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| INO | (6.6 M) | (15.3 M) | (19.7 M) | (66 M) | (36.1 M) | (29.2 M) | (73.7 M) | (88.2 M) | (97 M) | (119.4 M) | (166.4 M) | (303.7 M) | (279.8 M) | (135.1 M) | (107.3 M) | (96.5 M) | (101.4 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| TTRX | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (1.8 M) | (2 M) | (2.1 M) |
| VTGN | (4.8 K) | (12.2 M) | (12.9 M) | (3 M) | (13.9 M) | (47.2 M) | (10.3 M) | (14.3 M) | (24.6 M) | (20.8 M) | (17.9 M) | (47.8 M) | (59.2 M) | (29.4 M) | (51.4 M) | (46.3 M) | (44 M) |
| AGEN | (18.1 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.5 M) | (87.9 M) | (127 M) | (120.7 M) | (159.7 M) | (107.7 M) | (180.9 M) | (23.9 M) | (220.1 M) | (245.8 M) | (227.2 M) | (204.5 M) | (194.3 M) |
Climb Bio and related stocks such as Entera Bio, Spero Therapeutics, and Seres Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Climb Bio financial statement analysis. It represents the amount of money remaining after all of Climb Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Climb Bio Competitive Analysis
The better you understand Climb Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Climb Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Climb Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Climb Bio Competition Performance Charts
Five steps to successful analysis of Climb Bio Competition
Climb Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Climb Bio in relation to its competition. Climb Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Climb Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Climb Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Climb Bio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Climb Bio position
In addition to having Climb Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaurants Thematic Idea Now
Restaurants
Entities that are involved in restaurant business, as well as coffee shop chains and other eateries. The Restaurants theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Climb Bio Correlation with its peers. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.